Sanofi believes in Novavax's vaccine strengths...Novavax (NVAX 11.63%) and Moderna (MRNA 2.81%) both entered the coronavirus vaccine race around the same time, in early pandemic days, and their shares soared -- in fact, Novavax rose the most, gaining 2,700% in 2020 compared to a 400% increase for Moderna. Investors were betting on the companies' coronavirus vaccine candidates and their ability to bring in billions of dollars in revenue.Moderna fared well, dominating the vaccine market along with big pharma ...

The S&P 500 is on the longest streak since February, partly buoyed by stocks with analyst upgrades. The Dow Jones Industrial Average is also increasing amid mixed economic signals, as consumer sentiment dropped to a six-month low due to heightened short-term inflation expectations. With the potential risk of 'stagflation' on the horizon, the markets may have to adjust to this possibility. Treasury 10-year yields again increased, and traders have fully anticipated a rate cut by November, with a second move l ...

A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy.Novavax (NVAX -6.34%) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with Sanofi. Understandably, Novavax's share price leaped on news of the potentially lucrative deal with the global pharmaceutical sector company. This has left the stock fairly valued, in the opinion of one analyst trackin ...

Novavax shares have soared and plummeted in recent years.After losing more than 90% of its value from a peak back in 2021, Novavax (NVAX 2.82%) stock has finally taken off. The biotech soared 190% in two trading sessions after announcing a $1.2 billion vaccine-licensing deal with French pharmaceutical giant Sanofi. The agreement removed one huge worry that's been weighing on the stock: Novavax's ability to continue operations. The vaccine maker issued a going concern early last year, warning that if uncerta ...

Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.Shares of the struggling vaccine developer Novavax (NVAX 47.63%) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant that wants to market Novavax's COVID-19 and influenza vaccines.The recent Novavax stock rally continued after the weekend and investors are right to wonder if it has more fuel to climb higher. ...

GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 15, 2024 Time: 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) Location: Encore Hotel in Las Vegas, NV Moderator: Alec Stranahan, PhD, Equity Research – U.S. Biopharma Novavax participant ...

Shares of Novavax, Inc. (NVAX) skyrocketed nearly 99% on Friday after announcing a multi-billion-dollar deal with pharma giant Sanofi (SNY) for its protein-based COVID-19 vaccine, Nuvaxovid.Sanofi Deal Breathes New LifeBeginning next year, Sanofi will gain rights to co-market Nuvaxovid globally, except in certain countries where Novavax has existing partnership agreements. The French drugmaker also has the sole license to develop and market the Novavax vaccine in combination with its influenza vaccine.In re ...

Shares of Novavax jumped as much as 50% on Monday as Wall Street cheered the company's new multibillion-dollar deal with French drugmaker Sanofi that sparked a dramatic turnaround for the struggling vaccine maker.Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it first issued in February 2023 due to major doubts about its ability to stay afloat."It really does help ...

Meme Mania: COVID-19 was the Perfect StormThe 2020 U.S. equity crash and subsequent rebound was the perfect storm for a unique event called the “Meme” stock craze. After the panic lows of March 2020, stocks bottomed, and the government started to pump liquidity into the market and everyday Americans with stimulus checks. With many people working remotely, confined to their homes, and with more money in their pockets, Americans started trading in the stock market.By 2021, a message board called “Wallstreetbe ...

Luis Alvarez Novavax (NASDAQ:NVAX) has just announced mixed Q1 2024 earnings with a beat on EPS and a miss on revenue. NVAX surged by around 175% in premarket trading as investors applauded that their net loss narrowed by around 50% year-over-year to $148M, thanks to a 16% increase in revenue. In addition, investors were relieved to see the removal of the company’s going concern notice in the 10-Q, which was one of the geneses of the ticker’s relentless sell-off. However, I believe the primary cause of ...